Thyroid hormone increases mannan-binding lectin levels

European Journal of Endocrinology

Volumn 153, Issue 5, 2005, Pages 643-649

  Dalkjær Riis, Anne Lene ^a   Hansen, Troels Krarup ^a   Thiel, Steffen ^b   Gravholt, Claus Højbjerg ^a   Gjedde, Signe ^a   Gormsen, Lars Christian ^a   Jørgensen, Jens Otto Lunde ^a   Weeke, Jørgen ^a   Møller, Niels ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MANNAN BINDING LECTIN; PLACEBO; THIAMAZOLE; THYROID HORMONE; THYROXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; WILCOXON SIGNED RANKS TEST;

ADULT; ANTITHYROID AGENTS; FEMALE; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; MALE; MANNOSE-BINDING LECTIN; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; METHIMAZOLE; MIDDLE AGED; SINGLE-BLIND METHOD; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE; THYROXINE; TRIIODOTHYRONINE;

EID: 27944464046     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02013     Document Type: Article

References (46)

1. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 2004 89 2595-2600.
2. Willerson JT & Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004 109 II2-II10.
3. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB & Jensenius JC. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997 386 506-510.
4. Gadjeva M, Takahashi K & Thiel S. Mannan-binding lectin - a soluble pattern recognition molecule. Molecular Immunology 2004 41 113-121.
5. Turner MW. The role of mannose-binding lectin in health and disease. Molecular Immunology 2003 40 423-429.
6. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH & Flyvbjerg A. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004 53 1570-1576.
7. Madsen HO, Videm V, Svejgaard A, Svennevig JL & Garred P. Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet 1998 352 959-960.
8. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S & Stahl GL. Complement activation after oxidative stress: role of the lectin complement pathway. American Journal of Pathology 2000 156 1549-1556.
9. Hegele RA, Ban MR, Anderson CM & Spence JD. Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. Journal of Investigative Medicine 2000 48 198-202.
10. Jordan JE, Montalto MC & Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001 104 1413-1418.
11. Ohlenschlaeger T, Garred P, Madsen HO & Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. New England Journal of Medicine 2004 351 260-267.
12. Steffensen R, Thiel S, Varming K, Jersild C & Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. Journal of Immunological Methods 2000 241 33-42.
13. Hansen TK, Thiel S, Dall R, Rosenfalck AM, Trainer P, Flyvbjerg A, Jorgensen JOL & Christiansen JS. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH. Journal of Clinical Endocrinology and Metabolism 2001 86 5383-5388.
14. Gravholt CH, Leth-Larsen R, Lauridsen AL, Thiel S, Hansen TK, Holmskov U, Naeraa RW & Christiansen JS. The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome. European Journal of Endocrinology 2004 150 355-362.
15. Hansen TK, Thiel S, Wouters PJ, Christiansen JS & van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. Journal of Clinical Endocrinology and Metabolism 2003 88 1082-1088.
16. Rugonfalvi-Kiss S, Endresz V, Madsen HO, Burian K, Duba J, Prohaszka Z, Karadi I, Romics L, Gonczol E, Fust G & Garred P. Association of Chlamydia pneumoniae with coronary artery disease and its progression is dependent on the modifying effect of mannose-binding lectin. Circulation 2002 106 1071-1076.
17. Klein I & Ojamaa K. Thyroid hormone and the cardiovascular system. New England Journal of Medicine 2001 344 501-509.
18. Toft AD & Boon NA. Thyroid disease and the heart. Heart 2000 84 455-460.
19. Peters A, Ehlers M, Blank B, Exler D, Falk C, Kohlmann T, Fruehwald-Schultes B, Wellhoener P, Kerner W & Fehm HL. Excess triiodothyronine as a risk factor of coronary events. Archives of Internal Medicine 2000 160 1993-1999.
20. Parle JV, Maisonneuve F, Sheppard MC, Boyle P & Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001 358 861-865.
21. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J & Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. New England Journal of Medicine 1998 338 712-718.
22. Biondi B, Palmieri EA, Lombardi G & Fazio S. Effects of subclinical thyroid dysfunction on the heart. Annals of Internal Medicine 2002 137 904-914.
23. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A & Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Annals of Internal Medicine 2000 132 270-278.
24. Riis ALD, Gravholt CH, Djurhuus CB, Nørrelund H, Jørgensen JOL, Weeke J & Møller N. Elevated regional lipolysis in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2002 87 4747-4753.
25. Thiel S, Moller-Kristensen M, Jensen L & Jensenius JC. Assays for the functional activity of the mannan-binding lectin pathway of complement activation. Immunobiology 2002 205 446-454.
26. Moller-Kristensen M, Jensenius JC, Jensen L, Thielens N, Rossi V, Arlaud G & Thiel S. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. Journal of Immunological Methods 2003 282 159-167.
27. Christ-Crain M, Meier C, Guglielmetti M, Huber PR, Riesen W, Staub JJ & Muller B. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003 166 379-386.
28. Jublanc C, Bruckert E, Giral P, Chapman MJ, Leenhardt L, Carreau V & Turpin G. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRP. Atherosclerosis 2004 172 7-11.
29. Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, De Meyer PHEM, Pijl H & Cohen AF. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 2001 11 153-160.
30. Pearce EN, Bogazzi F, Martino E, Brogioni S, Pardini E, Pellegrini G, Parkes AB, Lazarus JH, Pinchera A & Braverman LE. The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease. Thyroid 2003 13 643-648.
31. Weetman AP. Graves' disease. New England Journal of Medicine 2000 343 1236-1248.
32. Rapoport B, Chazenbalk GD, Jaume JC & McLachlan SM. The thyrotropin (TSH)-releasing hormone receptor: interaction with TSH and autoantibodies. Endocrine Reviews 1998 19 673-716.
33. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, Braverman LE & Roti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. Journal of Clinical Endocrinology and Metabolism 1996 81 2976-2979.
34. Siddiqi A, Monson JP, Wood DF, Besser GM & Burrin JM. Serum cytokines in thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism 1999 84 435-439.
35. Akalin A, Colak O, Alatas O & Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clinical Endocrinology 2002 57 125-129.
36. Wahrenberg H, Wennlund A & Hoffstedt J. Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism. European Journal of Endocrinology 2002 146 607-611.
37. Hidaka Y, Okumura M, Shimaoka Y, Takeoka K, Tada H & Amino N. Increased serum concentration of interleukin-5 in patients with Graves' disease and Hashimoto's thyroiditis. Thyroid 1998 8 235-239.
38. Hidaka Y, Okumura M, Fukata S, Shimaoka Y, Takeoka K, Tada H, Kuma K & Amino N. Increased serum concentration of interleukin-12 in patients with silent thyroiditis and Graves' disease. Thyroid 1999 9 149-153.
39. Mariotti S, Caturegli P, Barbesino G, Del Prete GF, Chiovato L & Pinchera A. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism. Journal of Endocrinological Investigation 1991 14 777-781.
40. Mariotti S, Caturegli P, Barbesino G, Marino M, Del Prete GF, Chiovato L, Tonacchera M, De Carli M & Pinchera A. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases. Clinical Endocrinology 1992 37 415-422.
41. Koukkou E, Panayiotidis P, Alevizou-Terzaki V & Thalassinos N. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1991 73 771-776.
42. Diekman MJ, van der Put NM, Blom HJ, Tijssen JG & Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clinical Endocrinology 2001 54 197-204.
43. Dimitriadis G, Baker B, Marsh H, Mandarino L, Rizza R, Bergman R, Haymond M & Gerich J. Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. American Journal of Physiology 1985 248 E593-E601.
44. Valdimarsson H, Vikingsdottir T, Bang P, Saevarsdottir S, Gudjonsson JE, Oskarsson O, Christiansen M, Blou L, Laursen I & Koch C. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scandinavian Journal of Immunology 2004 59 97-102.
45. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiological Review 2001 81 1097-1142.
46. Sørensen CM, Hansen TK, Steffensen R, Jensenius JC & Thiel S. Abstract: Hormonal regulation of mannan-binding lectin synthesis in cultured hepatocytes. European Congress of Endocrinology, Göteborg 2005.